Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges

Overview of attention for article published in Current Hematologic Malignancy Reports, June 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#17 of 449)
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 2 news outlets
twitter: 4 X users

patent: 5 patents

Citations

dimensions_citation: 71 Dimensions

Readers on

mendeley: 226 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 5 patents that reference this research output.

Combining iPSC-derived effector cell types for immunotherapy use

Application CN-116096386-A

China

ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS

Application WO-2022098914-A1

World Intellectual Property Organisation (WIPO)

ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL

Application WO-2022098925-A1

World Intellectual Property Organisation (WIPO)

IMMUNE CELLS DEFECTIVE FOR SOCS1

Application WO-2022023576-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 1 additional patents.